Below is a list of forthcoming submissions that have recently been added to the SMS's work programme.  

• Abacavir sulfate with dolutegravir sodium and lamivudine (Triumeq)
• Albiglutide (Eperzan)
• Apixaban (Eliquis)
• Azelastine hydrochloride with fluticasone propionate (Dymista)
• Brimonidine tartrate (Mirvaso)
• Cabozanitib maleate (Cometriq)
• Canagliflozin hemihydrate with metformin hydrochloride (Vokanamet)
• Clindamycin (Treclin)
• Dabrafenib mesylate (Tafinlar)
• Follitropin alfa (Bemfola)
• Infliximab (Inflectra)
• Infliximab (Remsima)
• Paclitaxel (nanoparticle albumin bound) (Abraxane)
• Nintedanib (Vargatef)
• Olodaterol hydrochloride (Striverdi Respimat)
• Omalizumab (Xolair)
• Peginterferon beta-1a (Plegridy)
• Pomalidomide (Imnovid)
• Posaconazole (Noxafil)
• Ruxolitinib phosphate (Jakavi)
• Tiotropium bromide monohydrate (Spiriva)

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/Forthcoming_Submissions